Organization (Industry)
Intersect ENT (United States)
ClinicalTrials.gov lists Intersect ENT (United States) as lead sponsor of 12 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Intersect ENT (United States): 12 lead-sponsored trials and 1 legal-entity registration. The parent company on record for Intersect ENT (United States) is MEDTRONIC PUBLIC LIMITED COMPANY, which does not have its own page on this site.
Disease areas (3)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Nasal Polyps | 3 |
| Polyps | 3 |
| Disease | 2 |
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 3 |
| 2013 | 2 |
| 2009 | 2 |
| 2008 | 1 |
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 3 hit target (n=3) | 2 of 2 on time (n=2) |
Journals published in (3)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| International forum of allergy & rhinology | 4 |
| JAMA otolaryngology-- head & neck surgery | 1 |
| The Laryngoscope | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 47 | 11 | 2025-09-02 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 6 |
FDA recalls (2)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| SINUVA (mometasone furoate) sinus implant, 1350 mcg, 1 implant per pouch, Rx Only, intersect ENT, 1555 Adams Drive, Menlo Park, CA 94025, NDC 10599-003-01. | Class III | 2023-01-04 |
| Propel Mini Mometasone Furoate Sinus Implant, with Straight Delivery System, REF 60044 | Class II | 2022-10-21 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| INTERSECT ENT | Menlo Park, US | FDA |
Latest dated events (69)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-09-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-07 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2024-08-20 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-11-28 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-06-13 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 69 events.
Biomarker capability evidence (9)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| NADK | Trial sponsor | Named in trial inclusion criteria |
| NADK | Trial sponsor | Named in trial inclusion criteria |
| NADK | Trial sponsor | Primary endpoint in a Phase 3 trial |
| NADK | Trial sponsor | Primary endpoint in a Phase 3 trial |
| NADK | Trial sponsor | Mentioned in trial text |
Showing 5 of 9 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.